← Back to Screener
Alkermes Inc. plc (ALKS)
Price$34.23
Favorite Metrics
Price vs S&P 500 (26W)1.89%
Price vs S&P 500 (4W)13.17%
Market Capitalization$5.73B
P/E Ratio (Annual)23.69x
All Metrics
P/CF (Annual)11.00x
Book Value / Share (Quarterly)$10.99
P/TBV (Annual)2.54x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)9.90%
Cash Flow / Share (Quarterly)$2.90
Price vs S&P 500 (YTD)19.27%
Gross Margin (TTM)86.69%
Net Profit Margin (TTM)16.37%
EPS (TTM)$1.43
10-Day Avg Trading Volume2.10M
EPS Excl Extra (TTM)$1.43
Revenue Growth (5Y)7.28%
EPS (Annual)$1.43
ROI (Annual)13.28%
Gross Margin (Annual)86.69%
Net Profit Margin (5Y Avg)8.60%
Cash / Share (Quarterly)$3.55
P/E Basic Excl Extra (TTM)23.69x
Revenue Growth QoQ (YoY)-10.57%
P/E Normalized (Annual)23.69x
ROA (Last FY)9.72%
Revenue Growth TTM (YoY)-5.25%
EBITD / Share (TTM)$1.56
ROE (5Y Avg)9.68%
Operating Margin (TTM)17.21%
Cash Flow / Share (Annual)$2.90
P/B Ratio3.15x
P/B Ratio (Quarterly)2.54x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)3.62x
Net Interest Coverage (TTM)-39.80x
ROA (TTM)10.56%
EPS Growth QoQ (YoY)-67.15%
EV / EBITDA (TTM)20.21x
EPS Incl Extra (Annual)$1.43
Current Ratio (Annual)3.55x
Quick Ratio (Quarterly)3.04x
3-Month Avg Trading Volume2.21M
52-Week Price Return26.95%
EV / Free Cash Flow (Annual)11.11x
P/E Incl Extra (TTM)23.69x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$10.98
P/S Ratio (Annual)3.88x
Asset Turnover (Annual)0.59x
52-Week High$36.48
Operating Margin (5Y Avg)10.71%
EPS Excl Extra (Annual)$1.43
CapEx CAGR (5Y)-0.86%
Tangible BV CAGR (5Y)13.73%
26-Week Price Return10.64%
Quick Ratio (Annual)3.04x
13-Week Price Return12.77%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.55x
Enterprise Value$5,337.173
Revenue / Share Growth (5Y)5.98%
Asset Turnover (TTM)0.65x
Book Value / Share Growth (5Y)10.39%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.04x
Pretax Margin (Annual)19.75%
Cash / Share (Annual)$3.55
3-Month Return Std Dev52.03%
Gross Margin (5Y Avg)83.86%
Net Income / Employee (TTM)$0
EBITDA Interim CAGR (5Y)48.48%
ROE (Last FY)13.28%
Net Interest Coverage (Annual)411.73x
EPS Basic Excl Extra (Annual)$1.43
P/FCF (TTM)11.92x
Receivables Turnover (TTM)4.08x
EV / Free Cash Flow (TTM)11.11x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$1.43
Receivables Turnover (Annual)4.08x
ROI (TTM)14.45%
P/S Ratio (TTM)3.88x
Pretax Margin (5Y Avg)11.04%
Revenue / Share (Annual)$8.75
Tangible BV / Share (Annual)$10.98
Forward P/E42.48x
Free OCF CAGR (5Y)63.91%
Price vs S&P 500 (52W)-8.15%
P/E Ratio (TTM)23.69x
EPS Growth TTM (YoY)-34.37%
Year-to-Date Return23.41%
5-Day Price Return2.31%
EPS Normalized (Annual)$1.43
ROA (5Y Avg)6.76%
Net Profit Margin (Annual)16.37%
Month-to-Date Return-2.35%
Cash Flow / Share (TTM)$1.73
EBITD / Share (Annual)$1.56
Operating Margin (Annual)17.21%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)11.00x
ROI (5Y Avg)9.38%
P/E Excl Extra (TTM)23.69x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$1.43
P/TBV (Quarterly)2.54x
P/B Ratio (Annual)2.54x
Inventory Turnover (TTM)1.03x
Pretax Margin (TTM)19.75%
Book Value / Share (Annual)$10.99
Price vs S&P 500 (13W)9.90%
Beta0.29x
P/FCF (Annual)11.92x
Revenue / Share (TTM)$8.70
ROE (TTM)14.45%
52-Week Low$25.16
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.04
4.04
4.08
4.08
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ALKSAlkermes Inc. plc | 3.88x | -5.25% | 86.69% | — | $34.23 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Alkermes is a fully integrated biotechnology company specializing in pharmaceutical products for unmet medical needs through proprietary formulation technologies. The company develops products by partnering with third-party drug suppliers and licensees, providing integrated capabilities in research, development, manufacturing, and commercialization. Primary revenue comes from the U.S., with additional operations in Ireland and international markets.